Spread the love

Obesity Therapeutics

Two anti-obesity drugs were approved in June and July 2012, and GBI Research believes that only one, Vivus’ Qsymia, has a strong enough safety and efficacy (average placebo-adjusted weight loss of 5kg at the medium dose) profile to make a significant impact on the market, providing it is proven safe in long-term-use studies. If proven safe, GBI Research expects the sales of Qsymia and other drugs expected to be approved over the forecast period to increase the market size to $2.7 billion. Although moderate, this is significantly below the market potential given the size of the prevalence population. Optimally safe and effective anti-obesity drugs which overcome healthcare professionals’ negative opinions will have to be developed if the size of the market is ever to reflect the prevalence of obesity. Scope – The report analyzes the incidence of obesity, current treatment options, pipeline and market forecasts, and deals surrounding anti-obesity drugs. – A brief introduction to obesity; detailed analysis of recent, current and projected incidence trends; co-morbidities; economic implications of their treatment; and the current treatment options – Analysis of the currently marketed anti-obesity drugs, including recent sales figures, safety and efficacy data, and a discussion of each drug’s expected performance within the forecast period – Comprehensive reviews of the pipeline for anti-obesity drugs, including analysis by molecule type and mechanism of action – Statistical analysis of clinical trial duration, size, and failure rate by Phase and molecule type – An in-depth forecast model for the anti-obesity drugs market in the US, UK, France, Germany, Italy, Spain and Japan. Each model is based on the anticipated market performance of marketed drugs and those expected to be approved within the forecast period, and takes into account drug cost, efficacy, safety, and likely prescription volumes.

Content about Obesity

September 11, 2013 Nearly all doctors say that the sharp growth in Type 2 diabetes around the world and the obesity epidemic are linked to excess sugar consumption, according to a new report by the Credit Suisse Research Institute. September 3, 2013 The Walmart Foundation is donating $1.29 million to the Institute for America’s Health to expand its anti-obesity program at schools in major cities, the IAH said. August 29, 2013 Study uncovers new groups at risk of influenza complications new moms and obese people New mothers and obese people, two groups not typically regarded as risk groups, were found to have a higher risk of death and other severe outcomes from influenza, according to a global study sponsored by the World Health Organization that was released Tuesday. August 23, 2013 Stop & Shop recently sponsored a “Healthy Kids Summit” in Pawtucket, R.I., with help from local community health experts, the company said. August 15, 2013 Eisai, the U.S. pharmaceutical arm of Tokyo-based Eisai Co., announced the launch of a new website, “Closing the Gap: Obesity Management for Employers,” to provide employers with an educational resource for information about obesity management. August 8, 2013 Data released this week by federal health officials showed that between 2008 and 2011, the obesity rates of low-income preschoolers declined in 19-of-43 states and territories, according to the Centers for Disease Control and Prevention’s website. August 8, 2013 The sale of diet aids and weight-management products is booming approaching the $5 billion mark as an overall category across total multi-outlets, growing at a 12% clip.
Source:jccths.centerblog

adminBeautyDietsHealthanti-obesity,influenza,Obesity Therapeutics,weight loss
Two anti-obesity drugs were approved in June and July 2012, and GBI Research believes that only one, Vivus' Qsymia, has a strong enough safety and efficacy (average placebo-adjusted weight loss of 5kg at the medium dose) profile to make a significant impact on the market, providing it is proven...